SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia using assays for free and dissociated placental growth factor.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced registered direct offering of 13,333,334 shares of the Company’s common stock, at a purchase price of $1.50 per share, priced at a premium to market… Click here to view original post… […]
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that the company will participate in a pre-recorded presentation at the H.C. Wainwright BIOCONNECT Virtual Conference…. Click here to view original post… […]
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report second quarter 2021 financial results on Thursday, August 12, 2021 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30… Click here to view original post… […]
Copyright © 2022 Biotech Networks, LLC
